UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2023
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
England and Wales
(Jurisdiction
of Incorporation)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
Press Release entitled Outcome of audit tender dated
February
07, 2023
|
99.1
Haleon plc concludes tender for statutory audit
7 February 2023: In its prospectus published June
2022, Haleon plc (the "Company") (LSE/NYSE:
HLN) advised
that it expected to conduct an audit tender process for the audit
of the Company's financial statements for the year ending 31
December 2023, which would be subject to shareholder approval at
the Company's 2023 Annual General Meeting
(AGM).
Following the conclusion of a competitive tender process and
recommendation from the Company's Audit and Risk Committee, the
Board has approved the proposed appointment of KPMG LLP as its
statutory auditor following completion of the audit of its accounts
for the year ending 31 December 2022. This appointment will
be recommended to shareholders for approval at the 2023
AGM.
The Company would like to thank Deloitte LLP for their significant
contribution during their time as the Company's auditors, including
their work supporting the demerger and listing of Haleon as an
independent consumer health company. Subject to shareholder
approval at the 2023 AGM, we look forward to working with KPMG
LLP.
Ends
Contacts
Media
Zoë
Bird
+44 7736 746167
Investors Sonya Ghobrial
+44 7392 784784
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
HALEON
PLC
(Registrant)
|
|
Dated:
February 07,
2023
|
By:
|
/s/ Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|